Meeting
2024 ASCO Annual Meeting
A phase III trial comparing 5-FU plus cisplatin (CF) versus CF plus docetaxel or radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: 5-year follow-up from JCOG1109.
Authors
Ken Kato
Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Ken Kato , Yoshinori Ito , Hiroyuki Daiko , Soji Ozawa , Takashi Ogata , Hiroki Hara , Takashi Kojima , Tetsuya Abe , Takeo Bamba , Masaya Watanabe , Hirofumi Kawakubo , Yuichi Shibuya , Yasuhiro Tsubosa , Naoki Takegawa , Takeshi Kajiwara , Hideo Baba , Masaki Ueno , Ryunosuke Machida , Kenichi Nakamura , Yuko Kitagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Local-Regional Disease
Clinical Trial Registration Number
jRCTs031180202
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4082)
DOI
10.1200/JCO.2024.42.16_suppl.4082
Abstract #
4082
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Recurrence-free survival as a surrogate for overall survival in esophageal squamous cell carcinoma: Nationwide real-world data from Japan.
First Author: Jun Okui
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma.
First Author: Yuri Yoshinami
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Correlation between histopathological response by neoadjuvant DCF therapy and the clinical efficacy of palliative platinum-containing regimens for recurrent ESCC.
First Author: Shota Igaue
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Primary safety and short-term efficacy results for cohort E.
First Author: Takako Yoshii